Carbapenem resistant organisms: A 9-year surveillance and trends at Saint George University Medical Center

• Published in: Journal of infection and public health 2020-12, Vol.13 (12), p.2101-2106
• Main Authors: Chamieh, Amanda, El-Hajj, Gerard, Zmerli, Omar, Afif, Claude, Azar, Eid
• Format: Article
• Language: English
• Subjects: Academic Medical Centers; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Carbapenem resistant enterobacteriaceae; Carbapenem resistant organisms; Carbapenems - pharmacology; CRE epidemiology; Humans; Lebanon; Microbial Sensitivity Tests; Retrospective Studies
• ISSN: 1876-0341; 1876-035X
• DOI: 10.1016/j.jiph.2019.02.019

Carbapenem resistant organisms (CRO) constitute a large group of bacteria with different mechanisms of resistance and recently increasing global incidence. This rise has ambiguous dynamics and essential local epidemiologic data is lacking. In this retrospective study at the 400-bed Saint George Hospital (SGH) in Beirut, Lebanon, we retrieved electronic laboratory records of all intrinsic and acquired CRO isolates from January 1, 2010 until June 30, 2018. Isolation density was calculated as: number of isolates/1000PD. Analysis carried out using WHOnet with a trend time series analysis. During the study period, a total of 2150 non-duplicate CRO were isolated. While Acinetobacter baumanii (AB), Pseudomonas aeruginosa (CRPa), and Stenotrophomonas maltophilia (Sm) constituted 85% of total CRO in the study period, the carbapenem resistant enterobacteriaceae (CRE) rose from few sporadic cases before 2016 to a solid 32% of total CRO in 2018. Our most concrete trends were as follows. The rate of AB bacteremia was at an average of 0.114/1000 PD from 2011 to 2014. In 2015, a sudden doubling of AB bacteremia to 0.23/1000 PD. In 2017, there was a significant decrease to 0.113/1,000PD (p